Drug intelligence / Profile preview

Comparator 3 + alcohol + energy drink

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination product or experimental intervention consisting of three components: - "Comparator 3" (identity unspecified; likely a code name for an investigational or control substance in a clinical trial), - Alcohol (ethanol, a central nervous system depressant with sedative effects), - Energy drink (a beverage typically containing high levels of caffeine, sugar, taurine, B vitamins, and other stimulants). The combination of alcohol with energy drinks is well-documented to have unique pharmacological and behavioral effects compared to either component alone. Caffeine and other stimulants in the energy drink can mask the sedative effects of alcohol without reducing actual impairment. This leads to decreased perception of intoxication while increasing stimulation and desire to continue drinking. The result is often increased total alcohol consumption, higher risk behaviors (such as binge drinking), impaired judgment, greater risk for injury or accidents, dehydration, cardiovascular complications (elevated blood pressure/heart rate), arrhythmias, sleep disturbances, increased risk for addiction/dependence on both substances due to synergistic neurochemical interactions affecting dopamine pathways[1][2][4][5][7]. The specific mechanism by which this combination acts involves: - Alcohol potentiating GABAergic neurotransmission while inhibiting glutamatergic transmission, - Caffeine antagonizing adenosine receptors leading to increased alertness, - Potential modulation of dopamine release in reward pathways. This combination has been associated with public health concerns including increased rates of binge drinking among young people[1], higher incidence of risky sexual behavior[1], impaired driving[2], cardiovascular events[3][7], addiction potential[4][7], dehydration[2], sleep disruption[3] and even regulatory action against pre-mixed alcoholic energy drinks in some jurisdictions due to safety concerns[8].

Other names
Comparator 3 plus alcohol plus energy drinkComparator3 plus alcohol plus energy drinkComparator-3 plus alcohol plus energy drinkComparator 3 and alcohol and energy drinkComparator3 and alcohol and energy drinkComparator-3 and alcohol and energy drink
02

Targets

ADORA2A (Adenosine A₂A Receptor)GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on Comparator 3 + alcohol + energy drink.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Comparator 3 + alcohol + energy drink.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call